Ubs Asset Management Americas Inc Viridian Therapeutics, Inc.\De Transaction History
Ubs Asset Management Americas Inc
- $446 Billion
- Q3 2025
A detailed history of Ubs Asset Management Americas Inc transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 138,980 shares of VRDN stock, worth $3.99 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
138,980
Previous 190,104
26.89%
Holding current value
$3.99 Million
Previous $2.66 Million
12.5%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding VRDN
# of Institutions
184Shares Held
81.6MCall Options Held
39.6KPut Options Held
94.3K-
Deep Track Capital, LP Greenwich, CT5.38MShares$155 Million3.65% of portfolio
-
Black Rock Inc. New York, NY4.77MShares$137 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ4.43MShares$127 Million8.05% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.33MShares$125 Million0.0% of portfolio
-
Vr Adviser, LLC New York, NY3.88MShares$112 Million12.69% of portfolio
About Viridian Therapeutics, Inc.\DE
- Ticker VRDN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,888,900
- Market Cap $1.15B
- Description
- Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...